Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bleomycin + etoposide + doxorubicin + cyclophosphamide + vincristine + dacarbazine + prednisolone
- Development stage
- Unknown
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
BEACOPP-DAC (also referred to as BEACOPDac) is a multi-agent chemotherapy regimen primarily utilized for the treatment of classic Hodgkin lymphoma. It is a modified variant of the standard BEACOPP protocol, where the alkylating agent procarbazine is replaced with dacarbazine. This substitution is intended to reduce long-term toxicities, specifically lowering the risk of secondary malignancies and preserving fertility, while maintaining comparable efficacy to the original regimen. The protocol consists of bleomycin, etoposide, doxorubicin (Adriamycin), cyclophosphamide, vincristine (Oncovin), dacarbazine, and prednisolone. It is often administered in an escalated dose format (escalated BEACOPDac) for high-risk patients or those showing inadequate response on interim PET imaging. The regimen works through multiple mechanisms, including DNA alkylation, intercalation, topoisomerase II inhibition, and microtubule disruption.
- Other names
- BEACOPDacBEACOP-DAC
02
Targets
DNATOP2A (DNA topoisomerase II)GR (Glucocorticoid receptor)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on bleomycin + etoposide + doxorubicin + cyclophosphamide + vincristine + dacarbazine + prednisolone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bleomycin + etoposide + doxorubicin + cyclophosphamide + vincristine + dacarbazine + prednisolone.